These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35628654)

  • 21. New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines.
    Klejewski A; Świerczewska M; Zaorska K; Brązert M; Nowicki M; Zabel M; Januchowski R
    Anticancer Res; 2017 Apr; 37(4):1625-1636. PubMed ID: 28373423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
    Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
    Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.
    Liu MX; Siu MK; Liu SS; Yam JW; Ngan HY; Chan DW
    Oncotarget; 2014 Feb; 5(4):944-58. PubMed ID: 24659709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
    Lai J; Yang H; Zhu Y; Ruan M; Huang Y; Zhang Q
    BMC Cancer; 2019 Jun; 19(1):602. PubMed ID: 31215481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
    Zou J; Yin F; Wang Q; Zhang W; Li L
    Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines.
    Świerczewska M; Klejewski A; Wojtowicz K; Brązert M; Iżycki D; Nowicki M; Zabel M; Januchowski R
    Molecules; 2017 Oct; 22(10):. PubMed ID: 29027969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of miR-138-5p Sensitizes Taxol-Resistant Epithelial Ovarian Cancer Cells through Targeting Cyclin-Dependent Kinase 6.
    Liang M; Li Q; Shi S; Tian YN; Feng Y; Yang Y; Dong M; Zhang J; He J
    Gynecol Obstet Invest; 2021; 86(6):533-541. PubMed ID: 34818258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
    Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR
    Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells.
    Miyamoto M; Sawada K; Nakamura K; Yoshimura A; Ishida K; Kobayashi M; Shimizu A; Yamamoto M; Kodama M; Hashimoto K; Kimura T
    Sci Rep; 2020 Oct; 10(1):16755. PubMed ID: 33028939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA expression profiles associated with development of drug resistance in Ehrlich ascites tumor cells.
    Husted S; Søkilde R; Rask L; Cirera S; Busk PK; Eriksen J; Litman T
    Mol Pharm; 2011 Dec; 8(6):2055-62. PubMed ID: 21899346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upregulation of miRNA-450b-5p targets ACTB to affect drug resistance and prognosis of ovarian cancer via the PI3K/Akt signaling pathway.
    Xie S; Su Y; Zhang J; Yin F; Liu X
    Transl Cancer Res; 2024 Sep; 13(9):4800-4812. PubMed ID: 39430863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of microRNAs in drug-resistant ovarian cancer cells.
    Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
    Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
    Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
    PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miRNA expression patterns in chemoresistant breast cancer tissues.
    Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
    Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma: potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma.
    Tuncer SB; Erdogan OS; Erciyas SK; Saral MA; Celik B; Odemis DA; Turkcan GK; Yazici H
    J Ovarian Res; 2020 Aug; 13(1):99. PubMed ID: 32854743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Doxorubicin and Cisplatin Modulate miR-21, miR-106, miR-126, miR-155 and miR-199 Levels in MCF7, MDA-MB-231 and SK-BR-3 Cells That Makes Them Potential Elements of the DNA-Damaging Drug Treatment Response Monitoring in Breast Cancer Cells-A Preliminary Study.
    Mizielska A; Dziechciowska I; Szczepański R; Cisek M; Dąbrowska M; Ślężak J; Kosmalska I; Rymarczyk M; Wilkowska K; Jacczak B; Totoń E; Lisiak N; Kopczyński P; Rubiś B
    Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA Expression Profiling of Epithelial Ovarian Cancer Identifies New Markers of Tumor Subtype.
    Rattanapan Y; Korkiatsakul V; Kongruang A; Siriboonpiputtana T; Rerkamnuaychoke B; Chareonsirisuthigul T
    Microrna; 2020; 9(4):289-294. PubMed ID: 32703147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
    Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
    World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts.
    Ricci JW; Lovato DM; Severns V; Sklar LA; Larson RS
    Mol Cancer Ther; 2016 Dec; 15(12):2853-2862. PubMed ID: 27671528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.